

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 22, 2009

Lightlake Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Nevada

333-139915

N/A

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

225-230 Queens Quay W, Toronto, ON

M5J2Y7

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code 416-841-5414

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.01 Changes in Registrant's Certifying Accountant.

On August 17, 2009, Madrona Ventures Inc. (the "Company") now known as Lightlake Therapeutics Inc. dismissed its auditing firm of Dale Matheson Carr-Hilton Labonte LLP. On the same date, August 17, 2009, the accounting firm of PS Stephenson & Co., P.C., CPA was engaged as the Company's new independent auditing firm. The decision to change auditing firms was approved by the board of directors of the Company.

Over the past two fiscal years our former auditor's report on our financial statements did not contain an adverse opinion, a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles. However, our former auditor has raised doubt in the Company's ability to continue as a going concern. In the two most recent fiscal years and the subsequent interim period through the date of dismissal the Company did not have any disagreements with our former auditing firm of Dale Matheson Carr-Hilton Labonte LLP on any matter of accounting principles or practice, financial statement disclosure, or auditing scope or procedure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lightlake Therapeutics Inc.

(Registrant)

Date 10/22/2009

/s/ Seijin Ki

(Signature)
Director and Secretary

October 22, 2009

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Re: Madrona Ventures Inc.

Ladies and Gentlemen:

We are the former independent accountants for Madrona Ventures Inc. (the "Company"). We have been furnished with a copy of the Company's response to Item 4.01 of Form 8-K/A disclosing our dismissal as independent public accountants of the Company. We confirm our agreement with the statements made in such disclosure insofar as they relate to our firm. We are not in a position to agree or disagree with the statements in such disclosure regarding the appointment of or consultations with new independent accountants by the Company.

Yours truly,

"DMCL"

Dale Matheson Carr-Hilton LaBonte LLP
Chartered Accountants
Barry Hartley, CA